Dyadic International (DYAI) Competitors $0.98 +0.01 (+1.05%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.99 +0.01 (+0.69%) As of 07/15/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. GNLX, TARA, ATOS, HURA, PROC, CCCC, ANIX, MIST, MCRB, and HLVXShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Genelux (GNLX), Protara Therapeutics (TARA), Atossa Genetics (ATOS), TuHURA Biosciences (HURA), Procaps Group (PROC), C4 Therapeutics (CCCC), Anixa Biosciences (ANIX), Milestone Pharmaceuticals (MIST), Seres Therapeutics (MCRB), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors Genelux Protara Therapeutics Atossa Genetics TuHURA Biosciences Procaps Group C4 Therapeutics Anixa Biosciences Milestone Pharmaceuticals Seres Therapeutics HilleVax Dyadic International (NASDAQ:DYAI) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Is DYAI or GNLX more profitable? Genelux has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Genelux's return on equity of -93.04% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-163.94% -233.69% -59.37% Genelux N/A -93.04%-74.17% Do institutionals and insiders believe in DYAI or GNLX? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 9.3% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, DYAI or GNLX? Dyadic International has higher revenue and earnings than Genelux. Dyadic International is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M8.45-$5.81M-$0.20-4.90Genelux$10K11,630.08-$29.87M-$0.88-3.50 Which has more volatility & risk, DYAI or GNLX? Dyadic International has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Genelux has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Do analysts prefer DYAI or GNLX? Dyadic International presently has a consensus target price of $6.00, suggesting a potential upside of 512.12%. Genelux has a consensus target price of $17.75, suggesting a potential upside of 476.30%. Given Dyadic International's higher possible upside, analysts clearly believe Dyadic International is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media refer more to DYAI or GNLX? In the previous week, Genelux had 2 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Genelux and 1 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.89 beat Genelux's score of 0.63 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Very Positive Genelux Positive SummaryGenelux beats Dyadic International on 9 of the 17 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.19M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-4.9020.2228.5419.58Price / Sales8.45299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book12.257.568.145.54Net Income-$5.81M-$55.11M$3.24B$257.73M7 Day Performance2.10%3.81%0.18%-0.08%1 Month Performance5.40%11.60%5.96%8.09%1 Year Performance-35.51%-2.11%26.24%13.02% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International3.1296 of 5 stars$0.98+1.1%$6.00+512.1%-31.0%$29.19M$3.49M-4.907Positive NewsGap UpGNLXGenelux1.2006 of 5 stars$2.90-2.7%$17.75+512.1%+17.6%$112.45MN/A-3.3010TARAProtara Therapeutics2.1423 of 5 stars$2.80-3.1%$20.50+632.1%+28.2%$111.50MN/A-1.6330ATOSAtossa Genetics3.1457 of 5 stars$0.85-0.4%$6.17+629.1%-34.7%$109.68MN/A-4.038Positive NewsHURATuHURA Biosciences1.3698 of 5 stars$2.40-3.2%$12.67+427.8%N/A$108.33MN/A0.00N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.7%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeCCCCC4 Therapeutics2.9997 of 5 stars$1.52+2.7%$12.00+689.5%-67.5%$105.09M$35.58M-1.03150Positive NewsANIXAnixa Biosciences2.92 of 5 stars$3.21-0.6%$9.00+180.4%-0.6%$104.04M$210K-8.455News CoverageMISTMilestone Pharmaceuticals2.737 of 5 stars$2.17+11.9%$7.00+222.6%-6.6%$103.72M$1M-2.7830Gap UpHigh Trading VolumeMCRBSeres Therapeutics3.4427 of 5 stars$10.85-8.6%$73.67+579.0%-38.4%$103.65M$126.32M-2.36330Positive NewsGap DownHLVXHilleVax2.0755 of 5 stars$2.05-0.5%$2.33+13.8%+21.7%$103.29MN/A-0.9520Positive News Related Companies and Tools Related Companies Genelux Alternatives Protara Therapeutics Alternatives Atossa Genetics Alternatives TuHURA Biosciences Alternatives Procaps Group Alternatives C4 Therapeutics Alternatives Anixa Biosciences Alternatives Milestone Pharmaceuticals Alternatives Seres Therapeutics Alternatives HilleVax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DYAI Stock Alerts